1997: Engineering degree, Conservatoire National des Arts et Métiers, Paris
1985: Technical diploma graduate, Conservatoire National des Arts et Métiers, Paris
1983: Biochemical technical cycle degree, Conservatoire National des Arts et Métiers, Paris
1979: Medical biology technician certificate, Ecole Supérieure de Biologie et de Biochimie, Paris

2000-today: Research and medical biology engineer, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris
1991-2000: Research technician in therapeutic trials, Hospital Bichat Claude Bernard, Paris
1980-1990: Medical biology technician, Laboratory of Virology, Hospital Bichat Claude Bernard, Paris

1996: University diploma in Molecular Biology, University Pierre and Marie Curie, Paris
1995: University diploma in ADN analysis by PCR, University Pierre and Marie Curie, Paris

Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.

2023

Coppée R, Chenane HR, Bridier-Nahmias A, Tcherakian C, Catherinot E, Collin G, Lebourgeois S, Visseaux B, Descamps D, Vasse M, Farfour E
Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021.
Virus Research 2023, 323, 198950.

2022

Ferré VM, Lebourgeois S, Menidjel R, Collin G, Chenane HR, Guindi MO, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Fidouh N, Visseaux B
Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine.
The Journal of Infection 2022, 84, 248-288.

Lebourgeois S, Menidjel R, Chenane HR, Ferré VM, Collin G, Damond F, Coppée R, Yazdanpanah Y, Timsit JF, Houhou-Fidouh N, Descamps D, Charpentier C, Visseaux B
Alpha (B.1.1.7) and Delta (B.1.617.2 - AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage.
The Journal of Infection 2022, 84, 418-467.

Ferré VM, Lebourgeois S, Chenane HR, Menidjel R, Masson C, Collin G, Visseaux B, Descamps D, Fidouh N, Charpentier C
Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
The Journal of Infection 2022, S0163-4453(22)00126-8.

Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2022, 17, 239-251.

Le Hingrat Q, Collin G, Damond F, Peytavin G, Lebourgeois S, Ghosn J, Bachelard A, Ferré VM, Matheron S, Descamps D, Charpentier C
In vitro analysis of the replicative capacity and phenotypic susceptibility to integrase inhibitors of HIV-2 mutants with integrase insertions.
The Journal of Antimicrobial Chemotherapy 2022, 77, 409-412.

Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D, and the ANRS CO5 HIV-2 cohort
Ibalizumab shows in vitro activity against group A and group B HIV-2 clinical isolates.
AIDS (London, England) 2022

Richetta C, Subra F, Malet I, Leh H, Charpentier C, Corona A, Collin G, Descamps D, Deprez E, Parissi V, Calvez V, Tramontano E, Marcelin AG, Delelis O
Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.
Journal of Virology 2022, 96, e0067622.

2021

Martin A, Storto A, Le Hingrat Q, Collin G, André B, Mallory A, Dangla R, Descamps D, Visseaux B, Gossner O
High-sensitivity SARS-CoV-2 group testing by digital PCR among symptomatic patients in hospital settings.
Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2021, 141, 104895.

Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C
Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements.
Journal of Virological Methods 2021, 291, 114086.

Lebourgeois S, Chenane HR, Houhou-Fidouh N, Menidjel R, Ferré VM, Collin G, Benmalek N, Coppée R, Larrouy L, Yazdanpanah Y, Timsit JF, Charpentier C, Descamps D, Visseaux B
Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants.
Frontiers in Cellular and Infection Microbiology 2021, 11, 792202.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E
Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.
Vaccines 2021, 9, 883.

Michiels Y, Houhou-Fidouh N, Collin G, Berger J, Kohli E
Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
Vaccines 2021, 9, 1140.

2020

Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V
New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus.
Journal of the American Academy of Dermatology 2020, 83, 1219-1222.

Visseaux B, Le Hingrat Q, Collin G, Ferré V, Storto A, Ichou H, Bouzid D, Poey N, de Montmollin E, Descamps D, Houhou-Fidouh N
Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection.
Journal of Clinical Virology 2020, 129, 104520.

Charpentier C, Peytavin G, Raffi F, Burdet C, Landman R, Lê MP, Katlama C, Collin G, Benalycherif A, Cabie A, Mentré F, Yazdanpanah Y, Descamps D, Joly V
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of Antimicrobial Chemotherapy 2020, 75, 1611-1617.

Visseaux B, Le Hingrat Q, Collin G, Bouzid D, Lebourgeois S, Le Pluart D, Deconinck L, Lescure FX, Lucet JC, Bouadma L, Timsit JF, Descamps D, Yazdanpanah Y, Casalino E, Houhou-Fidouh N, McAdam AJ
Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection.
Journal of Clinical Microbiology 2020, 58, e00630-20, /jcm/58/8/JCM.00630-20.atom.

Le Hingrat Q, Ghanem M, Cazes A, Visseaux B, Collin G, Descamps D, Charpentier C, Crestani B
No association between human herpesvirus or herpesvirus saimiri and idiopathic pulmonary fibrosis.
ERJ Open Research 2020, 6, 00243-2020.

2019

Ferré V, Ekouevi D, Gbeasor-Komlanvi F, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra A
Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.
Clinical Microbiology and Infection 2019, 25, 1560.e1-1560.e7.

Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK
Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 1019-1026.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, FNAfRoAaVH(CH2C
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Le Hingrat Q, Collin G, Lê M, Peytavin G, Visseaux B, Bertine M, Tubiana R, Karmochkine M, Valin N, Collin F, Lemaignen A, Bernard L, Damond F, Matheron S, Descamps D, Charpentier C, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO5 HIV-2 Cohort
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2019, 69, 657-667.

Samri A, Charpentier C, Diallo MS, Bertine M, Even S, Morin V, Oudin A, Parizot C, Collin G, Hosmalin A, Cheynier R, Thiébaut R, Matheron S, Collin F, Zoorob R, Brun-Vézinet F, Autran B, ANRS CO5 IMMUNOVIR-2 Study Group
Limited HIV-2 reservoirs in central-memory CD4 T-cells associated to CXCR6 co-receptor expression in attenuated HIV-2 infection.
PLoS pathogens 2019, 15, e1007758.

2018

Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B
Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads.
Journal of Virological Methods 2018, 257, 12-15.

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Le Hingrat Q, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C
Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58.
The Journal of Infectious Diseases 2018, 218, 1027-1036.

Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C, ANRS HIV-2 CO5 Cohort
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2018

Brunet-Possenti F, Charpentier C, Collin G, Descamps D, Descamps V
Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection.
The British Journal of Dermatology 2018, 179, 1179-1180.

2017

Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC
HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2431-2437.

Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C
Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
The Journal of Antimicrobial Chemotherapy 2017, 72, 2954-2955.

Malet I, Subra F, Charpentier C, Collin G, Descamps D, Calvez V, Marcelin AG, Delelis O
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
mBio 2017

Visseaux B, Collin G, Ichou H, Charpentier C, Bendhafer S, Dumitrescu M, Allal L, Cojocaru B, Desfrère L, Descamps D, Mandelbrot L, Houhou-Fidouh N
Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study.
PloS One 2017, 12, e0172809.

2016

Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P
HPV 16 in squamous cell carcinoma of 19th century tonsils.
The Lancet. Oncology 2016, 17, e477–e478.

Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D
Zika virus in the female genital tract.
The Lancet. Infectious Diseases 2016, 16, 1220.

Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C, ANRS CO5 HIV-2 Cohort
HIV-2 Vif Diversity Among Defective and Nondefective Sequences.
Journal of Acquired Immune Deficiency Syndromes (1999) 2016, 72, e9–e11.

2015

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.
AIDS (London, England) 2015, 29, 779–784.

Visseaux B, Charpentier C, Collin G, Bertine M, Peytavin G, Damond F, Matheron S, Lefebvre E, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
PloS One 2015, 10, e0134904.

2014

Avettand-Fenoel V, Damond F, Gueudin M, Matheron S, Mélard A, Collin G, Descamps D, Chaix ML, Rouzioux C, Plantier JC, ANRS-CO5 HIV-2 and the ANRS-AC11 Quantification Working Group
New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load.
Journal of Clinical Microbiology 2014, 52, 3017–3022.

2013

Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D
In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir.
AIDS (London, England) 2013, 27, 2959-2961.

2012

Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F, French ANRS HIV-2 CO5 Cohort
Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2012, 55, 1417-1425.

Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, ANRS CO 05 HIV-2 Cohort
Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool.
The Journal of Infectious Diseases 2012, 205, 111-120.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Liver International: Official Journal of the International Association for the Study of the Liver 2012, 32, 93-101.

Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraqueiro G, Moucari R, Leclerc L, Martinot-Peignoux M, Matheron S, Marcellin P
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Antiviral Therapy 2012, 17, 61-70.

2011

Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Antimicrobial Agents and Chemotherapy 2011, 55, 1293-1295.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.
Retrovirology 2011, 8, 68.

2010

Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
AIDS (London, England) 2010, 24, 2753-2755.

Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.
Antimicrobial Agents and Chemotherapy 2010, 54, 4016-4019.

Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.
Journal of Clinical Microbiology 2010, 48, 1413-1416.

2009

Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, Collin G, Descamps D, Damond F, Brun-Vezinet F, Nisole S, Margottin-Goguet F, Pancino G, Transy C
The human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1 DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
Journal of Virology 2009, 83, 4854-4860.

2008

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
The Journal of Antimicrobial Chemotherapy 2008, 62, 914-920.

Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, ANRS HIV-2 Co5 Cohort
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008, 22, 2045-2046.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial Agents and Chemotherapy 2008, 52, 1545-1548.

2007

Damond F, Roquebert B, Bénard A, Collin G, Miceli M, Yéni P, Brun-Vezinet F, Descamps D
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays.
Journal of Clinical Microbiology 2007, 45, 3436-3438.

2006

Makinson A, Masquelier B, Taieb A, Peytavin G, Waldner-Combernoux A, Collin G, Chêne G, Brun-Vézinet F, Raffi F, Le Moing V, Leport C, Descamps D
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
AIDS (London, England) 2006, 20, 1327-1329.

Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Antiviral Therapy 2006, 11, 701-705.

2005

Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, Campa P, Benard A, Chêne G, Brun-Vezinet F
Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay.
Journal of Clinical Microbiology 2005, 43, 4234-4236.

Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Journal of Virology 2005, 79, 9572-9578.

Damond F, Collin G, Matheron S, Peytavin G, Campa P, Delarue S, Taieb A, Bénard A, Chêne G, Brun-Vézinet F, Descamps D, French ANRS HIV-2 Cohort (ANRS CO 5 VIH-2)
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral Therapy 2005, 10, 861-865.

2004

Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, Pueyo S, Chêne G, Brun-Vézinet F, French ANRS HIV-2 Cohort Study Group
High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
Journal of Medical Virology 2004, 74, 197-201.

Lastere S, Dalban C, Collin G, Descamps D, Girard PM, Clavel F, Costagliola D, Brun-Vezinet F, NARVAL Trial Group (ANRS 088)
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
Antiviral Therapy 2004, 9, 221-227.

Damond F, Matheron S, Peytavin G, Campa P, Taieb A, Collin G, Delaunay C, Chêne G, Brun-Vézinet F, Descamps D
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Antiviral Therapy 2004, 9, 635-636.

2003

Apetrei C, Descamps D, Collin G, Robertson DL, Pandrea I, Groza P, Prisecariu L, Teodorescu I, Luca V, Brun-Vézinet F
HIV type 1 diversity in northeastern Romania in 200-2001 based on phylogenic analysis of pol sequences from patient failing antiretroviral therapy.
AIDS research and human retroviruses 2003, 19, 1155-1161.

2002

Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cécile A, Delaugerre C, Damond F, Marcelin AG, Matheron S, Simon A, Valantin MA, Katlama C, Brun-Vézinet F
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
Antiviral Therapy 2002, 7, 211-218.

1995

Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-Vézinet F
HIV-1 group O sensitivity to antiretroviral drugs.
AIDS (London, England) 1995, 9, 977-978.